Skip to main content

Advertisement

SpringerLink
Log in

Artificial Lipid Membrane Permeability Method for Predicting Intestinal Drug Transport: Probing the Determining Step in the Oral Absorption of Sulfadiazine; Influence of the Formation of Binary and Ternary Complexes with Cyclodextrins

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

We propose an in vitro permeability assay by using a modified lipid membrane to predict the in vivo intestinal passive permeability of drugs. Two conditions were tested, one with a gradient pH (pH 5.5 donor/pH 7.4 receptor) and the other with an iso-pH 7.4. The predictability of the method was established by correlating the obtained apparent intestinal permeability coefficients (Papp) and the oral dose fraction absorbed in humans (fa) of 16 drugs with different absorption properties. The Papp values correlated well with the absorption rates under the two conditions, and the method showed high predictability and good reproducibility. On the other hand, with this method, we successfully predicted the transport characteristics of oral sulfadiazine (SDZ). Also, the tradeoff between the increase in the solubility of SDZ by its complex formation with cyclodextrins and/or aminoacids and its oral permeability was assessed. Results suggest that SDZ is transported through the gastrointestinal epithelium by passive diffusion in a pH-dependent manner. These results support the classification of SDZ as a high/low borderline permeability compound and are in agreement with the Biopharmaceutics Classification Systems (BCS). This conclusion is consistent with the in vivo pharmacokinetic properties of SDZ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Nirasay S, Mouget Y, Marcotte I, Claverie J. Supported bilayer on a nanopatterned membrane as model PAMPA membranes. Int J Pharm. 2011;421(1):170–5. https://doi.org/10.1016/j.ijpharm.2011.09.013.

    Article  CAS  PubMed  Google Scholar 

  2. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem. 1998;41(7):1007–10. https://doi.org/10.1021/jm970530e.

    Article  CAS  PubMed  Google Scholar 

  3. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem. 2001;44(6):923–30. https://doi.org/10.1021/jm001020e.

    Article  CAS  PubMed  Google Scholar 

  4. Sugano K, Nabuchi Y, Machida M, Aso Y. Prediction of human intestinal permeability using artificial membrane permeability. Int J Pharm. 2003;257(1-2):245–51. https://doi.org/10.1016/S0378-5173(03)00161-3.

    Article  CAS  PubMed  Google Scholar 

  5. Sjögren E, Dahlgren D, Ross C, Lennemäs H. Human in vivo regional intestinal permeability: quantification using site-specific drug absorption data. Mol Pharm. 2015;12(6):2026–19. https://doi.org/10.1021/mp500834v.

    Article  PubMed  Google Scholar 

  6. Bujard A, Petit C, Carrupt P-A, Rudaz S, Schappler J. HDM-PAMPA to predict gastrointestinal absorption, binding percentage, equilibrium and kinetics constants with human serum albumin and using 2 end-point measurements. Eur J Pharm Sci. 2017;97:143–50. https://doi.org/10.1016/j.ejps.2016.11.001.

    Article  CAS  PubMed  Google Scholar 

  7. Stewart AM, Grass ME, Mudie DM, Morgen MM, Friesen DT, Vodak DT. Development of a biorelevant, material-sparing membrane flux test for rapid screening of bioavailability-enhancing drug product formulations. Mol Pharm. 2017;14(6):2032–46. https://doi.org/10.1021/acs.molpharmaceut.7b00121.

    Article  CAS  PubMed  Google Scholar 

  8. Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, et al. Highly predictive and interpretable models for PAMPA permeability. Biorg Med Chem. 2017;25(3):1266–76. https://doi.org/10.1016/j.bmc.2016.12.049.

    Article  CAS  Google Scholar 

  9. Tsinman O, Tsinman K, Sun N, Avdeef A. Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model. Pharm Res. 2011;28(2):337–63. https://doi.org/10.1007/s11095-010-0280-x.

    Article  CAS  PubMed  Google Scholar 

  10. Bicker J, Alves G, Fortuna A, Soares-da-Silva P. A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drugs candidates. Int J Pharm. 2016;501(1–2):102–11. https://doi.org/10.1016/j.ijpharm.2016.01.074.

    Article  CAS  PubMed  Google Scholar 

  11. Sinkó B, Garrigues TM, Balogh GT, Nagy ZK, Tsinman O, Avdeef A, et al. Skin-PAMPA: a new method for fast prediction of skin penetration. Eur J Pharm. 2012;45(5):698–707. https://doi.org/10.1016/j.ejps.2012.01.011.

    Article  Google Scholar 

  12. Bhardwaj R, Chandrasena G Optimal ADME properties for clinical candidate and investigational new drug (IND) package. In: Zhang D, Surapaneni S editors ADME-enabling technologies in drug design and development New Jersey: John Wiley & Sons, Hoboken; 2012. p. 15–28, DOI: https://doi.org/10.1002/9781118180778.ch2.

  13. Avdeef A. The rise of PAMPA. Expert Opinion Drug Metabolism Toxicology. 2005;1(2):325–42. https://doi.org/10.1517/17425255.1.2.325.

    Article  CAS  Google Scholar 

  14. Loftsson T, Konradsdottir F, Masson M. Development and evaluation of an artificial membrane for determination of drug availability. Int J Pharm. 2006;326(1-2):60–8. https://doi.org/10.1016/j.ijpharm.2006.07.009.

    Article  CAS  PubMed  Google Scholar 

  15. Loftsson T, ByskovVogensen S, Brewster M, Konráδsdóttir F. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci. 2007;96(10):2532–46. https://doi.org/10.1002/jps.20992.

    Article  CAS  PubMed  Google Scholar 

  16. Loftsson T, Brewster M. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol. 2011;63(9):1119–35. https://doi.org/10.1111/j.2042-7158.2011.01279.x.

    Article  CAS  PubMed  Google Scholar 

  17. Zoppi A, Quevedo MA, Delrivo A, Longhi MR. Complexation of sulfonamides with beta-cyclodextrin studied by experimental and theoretical methods. J Pharm Sci. 2010;99(7):3166–76. https://doi.org/10.1002/jps.22062.

    Article  CAS  PubMed  Google Scholar 

  18. Delrivo A, Zoppi A, Longhi M. Interaction of sulfadiazine with cyclodextrins in aqueous solution and solid state. Carbohyd Polym. 2012;87(3):1980–8. https://doi.org/10.1016/j.carbpol.2011.10.025.

    Article  CAS  Google Scholar 

  19. Delrivo A, Zoppi A, Granero G, Longhi M. Studies of ternary systems of sulfadiazine with β-cyclodextrin and aminoacids. Ars Pharm. 2016;57(4):167–76.

    Google Scholar 

  20. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed, a correlation using rat intestinal membrane permeability for passive and carrier mediated compounds. Pharm Res. 1988;5(10):651–4. https://doi.org/10.1023/A:1015927004752.

    Article  CAS  PubMed  Google Scholar 

  21. CDER/FDA, U. S. (2000). Guidances for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.

  22. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an insitu perfusion model for permeability determinations: utility for BCS Class I biowaiver requests. Mol Pharm 2006;3:686–694.

  23. Varma MV, Gardner I, Steyn J, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KD, El-Kattan AF. pH-dependent solubility and permeability criteria for provisional Biopharmaceutics Classification (BCS and BDDCS) in early drug discovery. Mol Pharm 2012;9:1199–1212.

  24. Kotecha J, Sha S, Rathod I, Subbaiah IR. Prediction of oral absorption in humans by experimental immobilized artificial membrane chromatography indices and physicochemical descriptors. Int J Pharm 2008;360:96–106.

  25. Larregieu CA, Benet LZ. Distinguishing between the permeability relationship with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm. 2014;11(4):1335–44. https://doi.org/10.1021/mp4007858.

  26. Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K. Optimized conditions of bio-mimetic artificial membrane permeation assay. Int J Pharm 2001;228:181–8.

  27. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evalueation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci 2006;27:354–362.

  28. Tam KY, Avdeef A, Tsinman O, Sun N. The permeation of amphoteric drugs through artificial membranes – An in combo absorption model based on paracellular and transmembrane permeability. J Med Chem 2010;53:392–401.

  29. Meadows KE, Nadappuram BP, Unwin PR. A new approach for the fabrication of microscale lipid bilayers at glass pipets: application to quantitative passive permeation visualization. Soft Matter. 2014;10(42):8433–41. https://doi.org/10.1039/C3SM51406D.

    Article  CAS  PubMed  Google Scholar 

  30. Flanagan SD, Takahashi LH, Liu X, Benet LZ. Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. J Pharm Sci. 2002;91(4):1169–77. https://doi.org/10.1002/jps.10099.

    Article  CAS  PubMed  Google Scholar 

  31. Granero G, Longhi M, Mora M, Junginger H, Midha K, Shah V, et al. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci. 2010;99(6):2544–56. https://doi.org/10.1002/jps.22030.

    Article  CAS  PubMed  Google Scholar 

  32. Incecayir T, Tsume Y, Amidon GL. Comparison of the permeability of metoprolol and labetalol in rat, mouse, and caco-2 cells: use as a reference standard for BCS classification. Mol Pharm. 2013;10(3):958–66. https://doi.org/10.1021/mp300410n.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernäs AGL. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm. 2010;7(5):1827–34. https://doi.org/10.1021/mp100175a.

    Article  CAS  PubMed  Google Scholar 

  34. Toyozo U, Yutaka S. Studies on the metabolism of sulfadiazine. II. quantitative separation of excrements in the human urine after administration of sulfadiazine. Chem Pharm Bull. 1966;14(7):687–91.

    Article  Google Scholar 

  35. Van Petten GR, Becking GC, Withey RJ, Lettau F. Studies on the physiological availability and metabolism of sulfonamides. I. sulfadiazine. J Clin Pharmacolog. 1971;11:27–34.

    Google Scholar 

  36. Männistö P, Tuomisto J, Sairs N-E, Lehtinen T. Pharmacokinetic studies with trimethoprim and different doses of sulfadiazine in healthy human subjects. Chemotherapy. 1973;19(5):289–98. https://doi.org/10.1159/000221467.

    Article  PubMed  Google Scholar 

  37. Vree TB, de Ven ES, Verwey-van W, et al. Isolation, identification and determination of sulfadiazine and its hydroxy metabolites and conjugates from man and Rhesus monkey by high-performance liquid chromatography. J Chromatograph B: Biomed Sci Applic. 1995;670(1):111–23. https://doi.org/10.1016/0378-4347(95)00163-D.

    Article  CAS  Google Scholar 

  38. Ritschel WA, Erni W. Bioavailability of sulfadiazine in rabbits using tablets prepared by direct compression and fluidized-bed granulation. J Pharm Sci. 1977;66(10):1438–41. https://doi.org/10.1002/jps.2600661023.

    Article  CAS  PubMed  Google Scholar 

  39. Nielsen P, Gyrd-Hansen N. Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. Res Vet Sci. 1994;56(1):48–52. https://doi.org/10.1016/0034-5288(94)90195-3.

    Article  CAS  PubMed  Google Scholar 

  40. Fine-Shamir N, Beig A, Zur M, Lindley D, Miller JM, Dahan A. Toward successful cyclodextrin based solubility-enabling formulations for oral delivery of lipophilic drugs: solubility-permeability trade-off, biorelevant dissolution, and the unstirred water layer. Mol Pharm. 2017;14(6):2138–46. https://doi.org/10.1021/acs.molpharmaceut.7b00275.

    Article  CAS  PubMed  Google Scholar 

  41. Beig A, Miller JM, Lindley D, Dahan A. Striking the optimal solubility-permeability balance in oral formulation development for lipophilic drugs: maximizing carbamazepine blood levels. Mol Pharm. 2017;14(1):319–27. https://doi.org/10.1021/acs.molpharmaceut.6b00967.

    Article  CAS  PubMed  Google Scholar 

  42. Holm R, Olesen NE, Hartvig RA, Jorgensen EB, Larsen DB, Westh P. Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats. Eur J Pharm Biopharm. 2016;101:9–14. https://doi.org/10.1016/j.ejpb.2016.01.007.

    Article  CAS  PubMed  Google Scholar 

  43. Amidon GL, Lennernås H, Shah VP, Crison JR. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge the assistance of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), the Secretaría de Ciencia y Técnica de la Universidad Nacional de Córdoba (SECyT-UNC), and Fondo para la Investigación Científica y Tecnológica (FONCYT) which provided support and facilities for this investigation. We also thank Ferromet S.A. (agent of Roquette in Argentina) for their donation of cyclodextrins and DROMEX SA Argentina for the gift of Lipoid 75.

Author information

Authors and Affiliations

  1. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) CONICET-UNC and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, X5000HUA, Córdoba, Argentina

    Alicia Delrivo, Carolina Aloisio, Marcela R. Longhi & Gladys Granero

Authors
  1. Alicia Delrivo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolina Aloisio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcela R. Longhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gladys Granero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcela R. Longhi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delrivo, A., Aloisio, C., Longhi, M.R. et al. Artificial Lipid Membrane Permeability Method for Predicting Intestinal Drug Transport: Probing the Determining Step in the Oral Absorption of Sulfadiazine; Influence of the Formation of Binary and Ternary Complexes with Cyclodextrins. AAPS PharmSciTech 19, 1437–1447 (2018). https://doi.org/10.1208/s12249-018-0965-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-018-0965-8

Key Words

Search

Navigation